Author:
Dinarvand Negar,Afarin Reza,Shakerian Elham,Bavarsad Samaneh Salehipour,Mohammadtaghvaei Narges
Publisher
Springer Science and Business Media LLC
Reference30 articles.
1. Higashi T, Friedman SL, Hoshida Y (2017) Hepatic stellate cells as key target in liver fibrosis. Adv Drug Deliv Rev 121:27–42
2. Wynn TA, Ramalingam TR (2012) Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat Med 18(7):1028–1040
3. Peng Y, Li L, Zhang X, Xie M, Yang C, Tu S et al (2019) Fluorofenidone affects hepatic stellate cell activation in hepatic fibrosis by targeting the TGF–β1/Smad and MAPK signaling pathways. Experimental Therapeutic Med 18(1):41–48
4. Wang Z, Du K, Jin N, Tang B, Zhang W (2023) Macrophage in liver fibrosis: identities and mechanisms. Int Immunopharmacol 120:110357
5. Li J, Guo C, Wu J (2021) The agonists of peroxisome proliferator-activated receptor-γ for liver fibrosis. Drug Des Devel Ther. :2619–2628